Phosphodiesterase 4 inhibitors have only marginal benefits in COPD

Issue: BCMJ, vol. 53 , No. 6 , July August 2011 , Pages 293 News

Giving patients with chronic obstructive pulmonary disease newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flare-up, but does not increase general quality of life. 

Roflumilast and cilomilast are members of a new class of medicines, and trials have now evaluated their safety and performance. A team of researchers looked at data from nine trials of roflumilast and 14 trials of cilomilast involving over 1000 patients. 

Treatment with a PDE4 inhibitor was associated with a reduced likelihood of COPD exacerbation, but more participants in the treatment groups experienced non-serious adverse events compared with controls, particularly gastrointestinal symptoms and head­ache. Roflumilast was associated with weight loss during the trial period. 

So far trials have run for only 1 year or less, indicating a need to look at longer-lasting effects. 

For more information, go to  www.thecochranelibrary.com.

. Phosphodiesterase 4 inhibitors have only marginal benefits in COPD. BCMJ, Vol. 53, No. 6, July, August, 2011, Page(s) 293 - News.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply